PMID- 35747454
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1753-4313 (Electronic)
IS  - 0969-6113 (Print)
IS  - 0969-6113 (Linking)
VI  - 28
IP  - 2
DP  - 2021
TI  - Eligibility for dapagliflozin in unselected patients hospitalised with 
      decompensated heart failure.
PG  - 18
LID - 10.5837/bjc.2021.018 [doi]
LID - 18
AB  - Patients with heart failure with reduced ejection fraction (HFrEF) who received 
      the sodium-glucose co-transport 2 inhibitor, dapagliflozin, in the DAPA-HF 
      (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) study have a 
      significant reduction in worsening heart failure (HF) and cardiovascular death. 
      It is uncertain what proportion of patients admitted to a large regional cardiac 
      centre with decompensated heart failure would be eligible for dapagliflozin 
      post-discharge based on their characteristics at discharge. The DAPA-HF study 
      criteria were retrospectively applied to a cohort of 521 consecutive patients 
      referred to the inpatient HF service in a tertiary cardiac centre in South West 
      Wales between April 2017 and April 2018. Inclusion criteria: left ventricular 
      ejection fraction (LVEF) < 40%, New York Heart Association (NYHA) class II-IV 
      symptoms and an elevated N-terminal pro-B-type naturietic peptide (NT-proBNP). 
      Exclusion criteria: systolic blood pressure (SBP) < 95 mmHg, estimated glomerular 
      filtration rate (eGFR) < 30 ml/min/1.73 m2 or type 1 diabetes mellitus. We did 
      not have complete NTproBNP data for the cohort, as it was not routinely measured 
      at the time in our institute. There were 478 patients, mean age 78 +/- 13 years, 
      57% male and 91% NYHA class II-IV symptoms, were included in the analysis. Of 
      these, 247 patients had HFrEF, 219 (46%) patients met the inclusion criteria, 231 
      (48%) were excluded as LVEF was > 40%, and 48 (10%) were excluded with NYHA class 
      I symptoms. Of the 219 patients who met the inclusion criteria, 13 (5.9%) had a 
      SBP < 95 mmHg, 48 (22%) had eGFR < 30 ml/min/1.73 m2, leaving 136 (28.5% of total 
      and 55% of those with HFrEF) who met DAPA-HF study criteria. In our study, 28.5% 
      of all heart failure admissions and 55% of patients with HFrEF would be eligible 
      for dapagliflozin post-discharge according to the DAPA-HF study entry criteria.
CI  - Copyright (c) 2021 Medinews (Cardiology) Limited.
FAU - Kurdi, Hibba
AU  - Kurdi H
AD  - Specialty Trainee in Cardiology Regional Cardiac Centre, Morriston Hospital, 
      Morriston, Swansea, SA6 6NL.
FAU - Shah, Parin
AU  - Shah P
AD  - Specialty Trainee in Cardiology Regional Cardiac Centre, Morriston Hospital, 
      Morriston, Swansea, SA6 6NL.
FAU - Barker, Simon
AU  - Barker S
AD  - Internal Medicine Trainee Regional Cardiac Centre, Morriston Hospital, Morriston, 
      Swansea, SA6 6NL.
FAU - Harris, Daniel
AU  - Harris D
AD  - Cardiac Pharmacist Regional Cardiac Centre, Morriston Hospital, Morriston, 
      Swansea, SA6 6NL.
FAU - Dicken, Benjamin
AU  - Dicken B
AD  - Consultant Cardiologist Regional Cardiac Centre, Morriston Hospital, Morriston, 
      Swansea, SA6 6NL.
FAU - Edwards, Carey
AU  - Edwards C
AD  - Consultant Cardiologist Regional Cardiac Centre, Morriston Hospital, Morriston, 
      Swansea, SA6 6NL.
FAU - Jenkins, Geraint
AU  - Jenkins G
AD  - Consultant Cardiologist Regional Cardiac Centre, Morriston Hospital, Morriston, 
      Swansea, SA6 6NL.
LA  - eng
PT  - Journal Article
DEP - 20210422
PL  - England
TA  - Br J Cardiol
JT  - The British journal of cardiology
JID - 9503762
PMC - PMC8822528
OTO - NOTNLM
OT  - acute heart failure
OT  - dapagliflozin
OT  - heart failure with reduced ejection fraction
OT  - sodium-glucose co-transport 2 (SGLT2) inhibitors
COIS- None declared.
EDAT- 2021/04/22 00:00
MHDA- 2021/04/22 00:01
PMCR- 2021/04/22
CRDT- 2022/06/24 02:14
PHST- 2022/06/24 02:14 [entrez]
PHST- 2021/04/22 00:00 [pubmed]
PHST- 2021/04/22 00:01 [medline]
PHST- 2021/04/22 00:00 [pmc-release]
AID - bjc.2021.018 [pii]
AID - 10.5837/bjc.2021.018 [doi]
PST - epublish
SO  - Br J Cardiol. 2021 Apr 22;28(2):18. doi: 10.5837/bjc.2021.018. eCollection 2021.